Mood disorders in the medically ill: Scientific review and recommendations

Dwight L. Evans; Dennis S. Charney; Lydia Lewis; Robert N. Golden; Jack M. Gorman; K. Ranga Rama Krishnan; Charles B. Nemeroff; J. Douglas Bremner; Robert M. Carney; James C. Coyne; Mahlon R. Delong; Nancy Frasure-Smith; Alexander H. Glassman; Philip W. Gold; Igor Grant; Lisa Gwyther; Gail Ironson; Robert L. Johnson; Andres M. Kanner; Wayne J. Katon; Peter G. Kaufmann; Francis J. Keefe; Terence Ketter; Thomas P. Laughren; Jane Leserman; Constantine G. Lyketsos; William M. McDonald; Bruce S. McEwen; Andrew H. Miller; Dominique Musselman; Christopher O'Connor; John M. Petitto; Bruce G. Pollock; Robert G. Robinson; Steven P. Roose; Julia Rowland; Yvette Sheline; David S. Sheps; Gregory Simon; David Spiegel; Albert Stunkard; Trey Sunderland; Paul Tibbits; William J. Valvo

doi:10.1016/j.biopsych.2005.05.001

Mood disorders in the medically ill: Scientific review and recommendations

Dwight L. Evans, Dennis S. Charney, Lydia Lewis, Robert N. Golden, Jack M. Gorman, K. Ranga Rama Krishnan, Charles B. Nemeroff, J. Douglas Bremner, Robert M. Carney, James C. Coyne, Mahlon R. Delong, Nancy Frasure-Smith, Alexander H. Glassman, Philip W. Gold, Igor Grant, Lisa Gwyther, Gail Ironson, Robert L. Johnson, Andres M. Kanner, Wayne J. KatonPeter G. Kaufmann, Francis J. Keefe, Terence Ketter, Thomas P. Laughren, Jane Leserman, Constantine G. Lyketsos, William M. McDonald, Bruce S. McEwen, Andrew H. Miller, Dominique Musselman, Christopher O'Connor, John M. Petitto, Bruce G. Pollock, Robert G. Robinson, Steven P. Roose, Julia Rowland, Yvette Sheline, David S. Sheps, Gregory Simon, David Spiegel, Albert Stunkard, Trey Sunderland, Paul Tibbits, William J. Valvo

School of Medicine

Research output: Contribution to journal › Review article › peer-review

755 Scopus citations

Abstract

Objective: The purpose of this review is to assess the relationship between mood disorders and development, course, and associated morbidity and mortality of selected medical illnesses, review evidence for treatment, and determine needs in clinical practice and research. Data Sources: Data were culled from the 2002 Depression and Bipolar Support Alliance Conference proceedings and a literature review addressing prevalence, risk factors, diagnosis, and treatment. This review also considered the experience of primary and specialty care providers, policy analysts, and patient advocates. The review and recommendations reflect the expert opinion of the authors. Study Selection/Data Extraction: Reviews of epidemiology and mechanistic studies were included, as were open-label and randomized, controlled trials on treatment of depression in patients with medical comorbidities. Data on study design, population, and results were extracted for review of evidence that includes tables of prevalence and pharmacological treatment. The effect of depression and bipolar disorder on selected medical comorbidities was assessed, and recommendations for practice, research, and policy were developed. Conclusions: A growing body of evidence suggests that biological mechanisms underlie a bidirectional link between mood disorders and many medical illnesses. In addition, there is evidence to suggest that mood disorders affect the course of medical illnesses. Further prospective studies are warranted.

Original language	English (US)
Pages (from-to)	175-189
Number of pages	15
Journal	Biological psychiatry
Volume	58
Issue number	3
DOIs	https://doi.org/10.1016/j.biopsych.2005.05.001
State	Published - Aug 1 2005

Keywords

Antidepressant therapy
Depression
Medical comorbidity
Mood disorders

ASJC Scopus subject areas

Biological Psychiatry

Access to Document

10.1016/j.biopsych.2005.05.001

Cite this

Evans, D. L., Charney, D. S., Lewis, L., Golden, R. N., Gorman, J. M., Krishnan, K. R. R., Nemeroff, C. B., Bremner, J. D., Carney, R. M., Coyne, J. C., Delong, M. R., Frasure-Smith, N., Glassman, A. H., Gold, P. W., Grant, I., Gwyther, L., Ironson, G., Johnson, R. L., Kanner, A. M., ... Valvo, W. J. (2005). Mood disorders in the medically ill: Scientific review and recommendations. Biological psychiatry, 58(3), 175-189. https://doi.org/10.1016/j.biopsych.2005.05.001

Evans, DL, Charney, DS, Lewis, L, Golden, RN, Gorman, JM, Krishnan, KRR, Nemeroff, CB, Bremner, JD, Carney, RM, Coyne, JC, Delong, MR, Frasure-Smith, N, Glassman, AH, Gold, PW, Grant, I, Gwyther, L, Ironson, G, Johnson, RL, Kanner, AM, Katon, WJ, Kaufmann, PG, Keefe, FJ, Ketter, T, Laughren, TP, Leserman, J, Lyketsos, CG, McDonald, WM, McEwen, BS, Miller, AH, Musselman, D, O'Connor, C, Petitto, JM, Pollock, BG, Robinson, RG, Roose, SP, Rowland, J, Sheline, Y, Sheps, DS, Simon, G, Spiegel, D, Stunkard, A, Sunderland, T, Tibbits, P & Valvo, WJ 2005, 'Mood disorders in the medically ill: Scientific review and recommendations', Biological psychiatry, vol. 58, no. 3, pp. 175-189. https://doi.org/10.1016/j.biopsych.2005.05.001

@article{f580e75ab75847bba741ad7f46b2b5f4,

title = "Mood disorders in the medically ill: Scientific review and recommendations",

abstract = "Objective: The purpose of this review is to assess the relationship between mood disorders and development, course, and associated morbidity and mortality of selected medical illnesses, review evidence for treatment, and determine needs in clinical practice and research. Data Sources: Data were culled from the 2002 Depression and Bipolar Support Alliance Conference proceedings and a literature review addressing prevalence, risk factors, diagnosis, and treatment. This review also considered the experience of primary and specialty care providers, policy analysts, and patient advocates. The review and recommendations reflect the expert opinion of the authors. Study Selection/Data Extraction: Reviews of epidemiology and mechanistic studies were included, as were open-label and randomized, controlled trials on treatment of depression in patients with medical comorbidities. Data on study design, population, and results were extracted for review of evidence that includes tables of prevalence and pharmacological treatment. The effect of depression and bipolar disorder on selected medical comorbidities was assessed, and recommendations for practice, research, and policy were developed. Conclusions: A growing body of evidence suggests that biological mechanisms underlie a bidirectional link between mood disorders and many medical illnesses. In addition, there is evidence to suggest that mood disorders affect the course of medical illnesses. Further prospective studies are warranted.",

keywords = "Antidepressant therapy, Depression, Medical comorbidity, Mood disorders",

author = "Evans, {Dwight L.} and Charney, {Dennis S.} and Lydia Lewis and Golden, {Robert N.} and Gorman, {Jack M.} and Krishnan, {K. Ranga Rama} and Nemeroff, {Charles B.} and Bremner, {J. Douglas} and Carney, {Robert M.} and Coyne, {James C.} and Delong, {Mahlon R.} and Nancy Frasure-Smith and Glassman, {Alexander H.} and Gold, {Philip W.} and Igor Grant and Lisa Gwyther and Gail Ironson and Johnson, {Robert L.} and Kanner, {Andres M.} and Katon, {Wayne J.} and Kaufmann, {Peter G.} and Keefe, {Francis J.} and Terence Ketter and Laughren, {Thomas P.} and Jane Leserman and Lyketsos, {Constantine G.} and McDonald, {William M.} and McEwen, {Bruce S.} and Miller, {Andrew H.} and Dominique Musselman and Christopher O'Connor and Petitto, {John M.} and Pollock, {Bruce G.} and Robinson, {Robert G.} and Roose, {Steven P.} and Julia Rowland and Yvette Sheline and Sheps, {David S.} and Gregory Simon and David Spiegel and Albert Stunkard and Trey Sunderland and Paul Tibbits and Valvo, {William J.}",

note = "Funding Information: We acknowledge the following grants and author affiliations: grant/research support from GlaxoSmithKline (DJB, DLM, AMK, TAK, AHM, CBN, BGP), National Institutes of Health (NIH) (RMC, RNG, IG, DLM, NFS, DS), Cephalon (DLE), National Institute of Mental Health (NIMH) (CHL, WMM, AHM, CBN, BGP), Novartis (AMK, TAK, KRK), Esai (AMK), Abbott (TAK, CHL, CBN), AstraZeneca (TAK, CBN), Bristol-Myers Squibb (TAK, CHL, CBN), Elan (TAK), Lilly (TAK, CHL, SPR, GES), Janssen (TAK, CHL, WMM, AHM, DLM, CBN, BGP), Shire (TAK), NIA (CHL), Cover White Foundation (CHL), Helen Bader Foundation (CHL), Alzheimer Association (CHL), Forest (CHL, DLM, CBN, BGP, SPR), Parke-Davis (CHL), Bayer (CHL), Pfizer/Eisai/Neurologic (CHL), AFSP (WMM, CBN), National Alliance for Research in Schizophrenia and Depression (WMM, CBN), Fuqua Foundation (WMM), NINDS (WMM), NeuroNetics (WMM), Schering Plough (AHM, DLM), National Heart, Lung, and Blood Institute (AHM), Dana Foundation (DLM), Pharmacia (DLM), Upjohn (DLM), Pfizer (CBN, DSS), Stanley Foundation/NAMI (CBN), Wyeth Ayerst (CBN, SPR, GES), Bristol Myers (SPR), GRISM (NFS), CIHR (NFS), FRIC-M (NFS), and Solvay (GES); consultant/advisor to Abbott (DSC, DLE, TAK, KRK, CBN), AstraZeneca (DSC, DLE, AHG), Bristol Myers Squibb (DSC, DLE, RNG), Neuroscience Education Institute (DSC), Organon (DSC, KRK, CHL, BGP, SPR), Otsuka America (DSC), Otsuka (DLE, KRK, CBN), Quintiles (DSC, CBN), Sepracor (KRK, DSC), Lilly (DLE, TAK, CHL, SPR), Forest (DLE, CHL, WMM, CBN, BGP, SPR), Janssen (DLE, TAK, CHL, WMM, CBN, BGP, TS), Johnson and Johnson (DLE, KRK), Pfizer (DLE, AHG, TAK, KRK, CHL, CBN, CMO, GES, TS), GlaxoSmithKline (DLE, AHG, TAK, KRK, CHL, CBN, CMO, BGP), Somerset (DLE, KRK), Wyeth (DLE, KRK, SPR), Ono Pharma (AHG), AstraZeneca (TAK, CHL, CBN, BGP), Bristol-Myers Squibb (TAK, CHL, CBN), Cephalon (TAK), Elan (TAK), Novartis (TAK, KRK, BGP), Shire (TAK), Amgen (KRK), Corcept (KRK, CBN), Cyberonics (KRK, WMM, CBN), Merck (KRK), NPS (KRK), Synaptic (KRK), Vela (KRK), Eisai (CHL), DuPont (CHL), NeuroLogic (CHL), NeuroNetics (WMM), Servier (BSM), France (BSM), Acadia (CBN), Cypress Biosciences (CBN), Wyeth-Ayerst (CBN), and Lundbeck (TS); speakers{\textquoteright} bureau of Pfizer (AHG, DLM, CBN, RGR, DSS), GlaxoSmithKline (AHG, RNG, AMK, WMM, DLM, CBN), AstraZeneca (AHG, WMM, TS), Organon (RNG, WMM, DLM), Abbott (AMK, CBN), Shire (AMK), UCB (AMK), Ortho McNeill (AMK), Elan (AMK), Wyeth (WMM), Janssen (WMM, CBN, TS), Forest (WMM, DLM, BGP, RGR), Cyberonics (WMM), Sepracor (BGP), and Lundbeck (TS); advisory boards of GlaxoSmithKline (RNG) and Ovation (RNG); Data Safety Monitoring Board member of the Duke Clinical Research Institute (RNG); reviewed grants for the NIH (RNG); travel support from the National Alzheimer{\textquoteright}s Association (LPG); support from GlaxoSmithKline (GHI); honoraria from Abbott (TAK), AstraZeneca (TAK), Bristol-Myers Squibb (TAK), Lilly (TAK), GlaxoSmithKline (TAK), Janssen (TAK), Novartis (TAK), and Pfizer (TAK); speaker for Parke-Davis (Warner-Lambert) (CHL), DuPont (CHL), Lilly (CHL), Janssen (CHL), Abbott (CHL), Bayer (CHL), Eisai (CHL), Pfizer (CHL), Bristol-Myers-Squibb (CHL), Novartis (CHL), Forest (CHL), and Lundbeck (CHL); support for Clinical Programs from Fuqua Foundation (WMM), Janssen (WMM) and Organon (WMM); stock in Amgen (WMM), Teva (WMM), Millenium (WMM), Pfizer (WMM), Abbott (WMM), Neurobiological Tech (WMM), Neurocrine (BSM, CBN), Corcept (BSM), Cypress Biosciences (CBN), and Acadia (CBN); Board of Directors of AFSP (CBN), APIRE (CBN), George West Mental Health Foundation (CBN), and Novadel Pharma (CBN); patents for method, and devices for transdermal delivery of lithium (US 6,375,990 B1) (CBN); method to estimate serotonin and norepinephrine transporter occupancy after drug treatment with patient or animal serum (provisional filing April, 2001) (CBN); and equity in Reevax (CBN), BMC-JR LLC (CBN). Copyright: Copyright 2008 Elsevier B.V., All rights reserved.",

year = "2005",

month = aug,

day = "1",

doi = "10.1016/j.biopsych.2005.05.001",

language = "English (US)",

volume = "58",

pages = "175--189",

journal = "Biological psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "3",

}

TY - JOUR

T1 - Mood disorders in the medically ill

T2 - Scientific review and recommendations

AU - Evans, Dwight L.

AU - Charney, Dennis S.

AU - Lewis, Lydia

AU - Golden, Robert N.

AU - Gorman, Jack M.

AU - Krishnan, K. Ranga Rama

AU - Nemeroff, Charles B.

AU - Bremner, J. Douglas

AU - Carney, Robert M.

AU - Coyne, James C.

AU - Delong, Mahlon R.

AU - Frasure-Smith, Nancy

AU - Glassman, Alexander H.

AU - Gold, Philip W.

AU - Grant, Igor

AU - Gwyther, Lisa

AU - Ironson, Gail

AU - Johnson, Robert L.

AU - Kanner, Andres M.

AU - Katon, Wayne J.

AU - Kaufmann, Peter G.

AU - Keefe, Francis J.

AU - Ketter, Terence

AU - Laughren, Thomas P.

AU - Leserman, Jane

AU - Lyketsos, Constantine G.

AU - McDonald, William M.

AU - McEwen, Bruce S.

AU - Miller, Andrew H.

AU - Musselman, Dominique

AU - O'Connor, Christopher

AU - Petitto, John M.

AU - Pollock, Bruce G.

AU - Robinson, Robert G.

AU - Roose, Steven P.

AU - Rowland, Julia

AU - Sheline, Yvette

AU - Sheps, David S.

AU - Simon, Gregory

AU - Spiegel, David

AU - Stunkard, Albert

AU - Sunderland, Trey

AU - Tibbits, Paul

AU - Valvo, William J.

N1 - Funding Information: We acknowledge the following grants and author affiliations: grant/research support from GlaxoSmithKline (DJB, DLM, AMK, TAK, AHM, CBN, BGP), National Institutes of Health (NIH) (RMC, RNG, IG, DLM, NFS, DS), Cephalon (DLE), National Institute of Mental Health (NIMH) (CHL, WMM, AHM, CBN, BGP), Novartis (AMK, TAK, KRK), Esai (AMK), Abbott (TAK, CHL, CBN), AstraZeneca (TAK, CBN), Bristol-Myers Squibb (TAK, CHL, CBN), Elan (TAK), Lilly (TAK, CHL, SPR, GES), Janssen (TAK, CHL, WMM, AHM, DLM, CBN, BGP), Shire (TAK), NIA (CHL), Cover White Foundation (CHL), Helen Bader Foundation (CHL), Alzheimer Association (CHL), Forest (CHL, DLM, CBN, BGP, SPR), Parke-Davis (CHL), Bayer (CHL), Pfizer/Eisai/Neurologic (CHL), AFSP (WMM, CBN), National Alliance for Research in Schizophrenia and Depression (WMM, CBN), Fuqua Foundation (WMM), NINDS (WMM), NeuroNetics (WMM), Schering Plough (AHM, DLM), National Heart, Lung, and Blood Institute (AHM), Dana Foundation (DLM), Pharmacia (DLM), Upjohn (DLM), Pfizer (CBN, DSS), Stanley Foundation/NAMI (CBN), Wyeth Ayerst (CBN, SPR, GES), Bristol Myers (SPR), GRISM (NFS), CIHR (NFS), FRIC-M (NFS), and Solvay (GES); consultant/advisor to Abbott (DSC, DLE, TAK, KRK, CBN), AstraZeneca (DSC, DLE, AHG), Bristol Myers Squibb (DSC, DLE, RNG), Neuroscience Education Institute (DSC), Organon (DSC, KRK, CHL, BGP, SPR), Otsuka America (DSC), Otsuka (DLE, KRK, CBN), Quintiles (DSC, CBN), Sepracor (KRK, DSC), Lilly (DLE, TAK, CHL, SPR), Forest (DLE, CHL, WMM, CBN, BGP, SPR), Janssen (DLE, TAK, CHL, WMM, CBN, BGP, TS), Johnson and Johnson (DLE, KRK), Pfizer (DLE, AHG, TAK, KRK, CHL, CBN, CMO, GES, TS), GlaxoSmithKline (DLE, AHG, TAK, KRK, CHL, CBN, CMO, BGP), Somerset (DLE, KRK), Wyeth (DLE, KRK, SPR), Ono Pharma (AHG), AstraZeneca (TAK, CHL, CBN, BGP), Bristol-Myers Squibb (TAK, CHL, CBN), Cephalon (TAK), Elan (TAK), Novartis (TAK, KRK, BGP), Shire (TAK), Amgen (KRK), Corcept (KRK, CBN), Cyberonics (KRK, WMM, CBN), Merck (KRK), NPS (KRK), Synaptic (KRK), Vela (KRK), Eisai (CHL), DuPont (CHL), NeuroLogic (CHL), NeuroNetics (WMM), Servier (BSM), France (BSM), Acadia (CBN), Cypress Biosciences (CBN), Wyeth-Ayerst (CBN), and Lundbeck (TS); speakers’ bureau of Pfizer (AHG, DLM, CBN, RGR, DSS), GlaxoSmithKline (AHG, RNG, AMK, WMM, DLM, CBN), AstraZeneca (AHG, WMM, TS), Organon (RNG, WMM, DLM), Abbott (AMK, CBN), Shire (AMK), UCB (AMK), Ortho McNeill (AMK), Elan (AMK), Wyeth (WMM), Janssen (WMM, CBN, TS), Forest (WMM, DLM, BGP, RGR), Cyberonics (WMM), Sepracor (BGP), and Lundbeck (TS); advisory boards of GlaxoSmithKline (RNG) and Ovation (RNG); Data Safety Monitoring Board member of the Duke Clinical Research Institute (RNG); reviewed grants for the NIH (RNG); travel support from the National Alzheimer’s Association (LPG); support from GlaxoSmithKline (GHI); honoraria from Abbott (TAK), AstraZeneca (TAK), Bristol-Myers Squibb (TAK), Lilly (TAK), GlaxoSmithKline (TAK), Janssen (TAK), Novartis (TAK), and Pfizer (TAK); speaker for Parke-Davis (Warner-Lambert) (CHL), DuPont (CHL), Lilly (CHL), Janssen (CHL), Abbott (CHL), Bayer (CHL), Eisai (CHL), Pfizer (CHL), Bristol-Myers-Squibb (CHL), Novartis (CHL), Forest (CHL), and Lundbeck (CHL); support for Clinical Programs from Fuqua Foundation (WMM), Janssen (WMM) and Organon (WMM); stock in Amgen (WMM), Teva (WMM), Millenium (WMM), Pfizer (WMM), Abbott (WMM), Neurobiological Tech (WMM), Neurocrine (BSM, CBN), Corcept (BSM), Cypress Biosciences (CBN), and Acadia (CBN); Board of Directors of AFSP (CBN), APIRE (CBN), George West Mental Health Foundation (CBN), and Novadel Pharma (CBN); patents for method, and devices for transdermal delivery of lithium (US 6,375,990 B1) (CBN); method to estimate serotonin and norepinephrine transporter occupancy after drug treatment with patient or animal serum (provisional filing April, 2001) (CBN); and equity in Reevax (CBN), BMC-JR LLC (CBN). Copyright: Copyright 2008 Elsevier B.V., All rights reserved.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Objective: The purpose of this review is to assess the relationship between mood disorders and development, course, and associated morbidity and mortality of selected medical illnesses, review evidence for treatment, and determine needs in clinical practice and research. Data Sources: Data were culled from the 2002 Depression and Bipolar Support Alliance Conference proceedings and a literature review addressing prevalence, risk factors, diagnosis, and treatment. This review also considered the experience of primary and specialty care providers, policy analysts, and patient advocates. The review and recommendations reflect the expert opinion of the authors. Study Selection/Data Extraction: Reviews of epidemiology and mechanistic studies were included, as were open-label and randomized, controlled trials on treatment of depression in patients with medical comorbidities. Data on study design, population, and results were extracted for review of evidence that includes tables of prevalence and pharmacological treatment. The effect of depression and bipolar disorder on selected medical comorbidities was assessed, and recommendations for practice, research, and policy were developed. Conclusions: A growing body of evidence suggests that biological mechanisms underlie a bidirectional link between mood disorders and many medical illnesses. In addition, there is evidence to suggest that mood disorders affect the course of medical illnesses. Further prospective studies are warranted.

AB - Objective: The purpose of this review is to assess the relationship between mood disorders and development, course, and associated morbidity and mortality of selected medical illnesses, review evidence for treatment, and determine needs in clinical practice and research. Data Sources: Data were culled from the 2002 Depression and Bipolar Support Alliance Conference proceedings and a literature review addressing prevalence, risk factors, diagnosis, and treatment. This review also considered the experience of primary and specialty care providers, policy analysts, and patient advocates. The review and recommendations reflect the expert opinion of the authors. Study Selection/Data Extraction: Reviews of epidemiology and mechanistic studies were included, as were open-label and randomized, controlled trials on treatment of depression in patients with medical comorbidities. Data on study design, population, and results were extracted for review of evidence that includes tables of prevalence and pharmacological treatment. The effect of depression and bipolar disorder on selected medical comorbidities was assessed, and recommendations for practice, research, and policy were developed. Conclusions: A growing body of evidence suggests that biological mechanisms underlie a bidirectional link between mood disorders and many medical illnesses. In addition, there is evidence to suggest that mood disorders affect the course of medical illnesses. Further prospective studies are warranted.

KW - Antidepressant therapy

KW - Depression

KW - Medical comorbidity

KW - Mood disorders

UR - http://www.scopus.com/inward/record.url?scp=23444451611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23444451611&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2005.05.001

DO - 10.1016/j.biopsych.2005.05.001

M3 - Review article

C2 - 16084838

AN - SCOPUS:23444451611

SN - 0006-3223

VL - 58

SP - 175

EP - 189

JO - Biological psychiatry

JF - Biological psychiatry

IS - 3

ER -

Mood disorders in the medically ill: Scientific review and recommendations

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this